We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FIPP Frontier Ip Group Plc

0.00 (0.0%)
08 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Frontier Ip Group Plc LSE:FIPP London Ordinary Share GB00B63PS212 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 40.50 68,373 08:00:00
Bid Price Offer Price High Price Low Price Open Price
39.00 42.00 40.50 40.50 40.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Real Estate Agents & Mgrs 372k -3.24M -0.0582 -6.96 22.57M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:11:19 O 13 42.00 GBX

Frontier Ip (FIPP) Latest News

Frontier Ip (FIPP) Discussions and Chat

Frontier Ip Forums and Chat

Date Time Title Posts
21/11/202320:13Frontier IP562
30/7/201122:11Why have they bothered1

Add a New Thread

Frontier Ip (FIPP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Frontier Ip (FIPP) Top Chat Posts

Top Posts
Posted at 10/12/2023 08:20 by Frontier Ip Daily Update
Frontier Ip Group Plc is listed in the Real Estate Agents & Mgrs sector of the London Stock Exchange with ticker FIPP. The last closing price for Frontier Ip was 40.50p.
Frontier Ip currently has 55,734,553 shares in issue. The market capitalisation of Frontier Ip is £22,572,494.
Frontier Ip has a price to earnings ratio (PE ratio) of -6.96.
This morning FIPP shares opened at 40.50p
Posted at 02/11/2023 11:10 by rivaldo
For the record, here's the IC's new FIPP tip:

"Bag a technology bargain buy

A 50 per cent discount to NAV is harsh given the operational progress being made by the group’s investee companies

NAV falls 6.5 per cent to £45.5mn (81.8p)
Cash and listed stake in Exscentia currently worth £6.2mn (11.1p)
Progress on multiple investee companies

Shares in Edinburgh-based FrontierIP (FIPP:41.5p), a technology investment company that provides commercialisation services to university spin-outs in return for ‘free equity’stakes, dipped 10 per cent post annual results.The fall was caused by an unexpected 6.5 percent (£3.1mn) reversal in net asset value (NAV)after the group booked a £2.2mn unrealised loss on its 17 per cent stake in The Vaccine Group(TVG).

TVG is creating a range of vaccines based on a novel herpes virus-based platform to prevent the spread of economically damaging diseases in livestock. The company now has eight vaccine candidates approaching proof of principle. Its most advanced projects are for pigs. During the year, TVG successfully developed a vaccine candidate for streptococcus suis, a bacterial disease carried by pigs that causes productivity losses as well as meningitis and other symptoms in humans. The project was funded by the UK and Chinese governments.

In addition to streptococcus suis, TVG has developed a transmissible candidate vaccine against a virus called Lassa fever for use in ratsthat spread the disease. Funded by a US government agency, a small-scale trial showed the candidate could be transmitted between rats,significantly improving their immunity to Lassa fever and reducing its spread between them. The company is in discussions with potential partners.Progress on monetising its technology will be needed to drive TVG’s valuation higher, but that’s not out of the question.

It’s something that Plymouth spin-out, green technology company Pulsiv Solar, the group’s largest holding, is already doing. Its on-chip technology not only improves the energy efficiency of power supplies, battery chargers, LED lighting and photovoltaic solar cells, but is proving popular with leading electronic component suppliers around the world looking to exploit the commercial opportunity. A £1.5mn fundraising placed a £50mn pre-money valuation on Pulsiv,which means that Frontier’s 18.2 per cent equity stake has a read-through valuation of £9.4mn,accounting for 28 per cent of its £33mn equity portfolio at the 30 June 2023 financial year-end.

The operational progress of harvest robotics developer Fieldwork Robotics, a spin-out from the University of Plymouth, is also attracting investor interest. Post Frontier’s financial year-end, the company secured a £1.5mn investmentfrom Elbow Beach Capital, a decarbonisation,sustainability and social impact investor, and attracted £1.5mn of investment from 575 investors in a Seedrs funding round. The £7.2mn pre-money valuation placed a £1.6mn value on Frontier’s equity stake. Having developed the world's first raspberry-harvesting robots to improve farm efficiency, reduce food wastage and help solve the problem of worker shortages,the funds raised are being used to grow Fieldworks’ team, outsource robot manufactureand attract more farmers to its harvest-as-a-service offering.

It’s a similar positive story at Cambridge University spin-out CamGraPhIC. The company’s graphene-based photonics run at higher speeds and lower temperatures than equivalent technologies – and therefore use less energy. Datacentres, which consume around 1 per cent of global energy output, are one potential marketfor its optical transceivers. Sir Michael Rake,former chair of BT Group(BT.A), invested in CamGraPhIC’s latest funding round, which raised £1.26mn to complete the fabrication and testing of demonstration devices with multinational companies. The technology is starting to gain traction with governmental organisations, too. In the financial year, Frontier booked a £1.4mn gain on its 20.8 per cent stake in CamGraPhIC, in line with the fundraising valuation, and a £0.7mn gain on its £2.6mn loan note holding.

Deep discount to sum-of-the-parts valuations

Post period end, Frontier IP subscribed for a further £1.3mn of CamGraPhIC loan notes (of which £0.8mn was classified as Advances in the2023 accounts) to accelerate its development.The investment reduces group pro-forma cash to £4.1mn. In addition, Frontier intends to dispose of more shares in Nasdaq-listed Exscientia (US:Exscientia(EXAI), a clinical-stage pharma technology company pioneering the use of artificial intelligence (AI) to design new drugs. Frontier currently holds 0.49mn Exscientia shares worth $2.5mn (£2.1mn) at the current market price.

Effectively, the liquid stake in Exscientia and pro-forma cash are worth £6.2mn (11.1p) or a quarter of the group’s market capitalisation of £23mn (41.5p). It means that Frontier’s £33mn(59p) equity portfolio, £5.9mn (10.5p) of debt investments and £1mn (1.8p) of trade receivables are in the share price for 58 per cent less than their combined carrying valuations.That̵7;s extremely harsh given the progress being made by both CamGraPhIC and Pulsiv Solar. In fact, I would be surprised if their combined valuation doesn’t exceed Frontier’s current market capitalisation within the next 18-24months.So, having made a case to buy Frontier’s shares,at 38p, ahead of the results (‘A tech buy on a 57 per cent discount’, 13 September 2023), I see scope for positive newsflow from portfolio companies to narrow the 50 per cent share price discount to NAV over the coming months. Buy"
Posted at 31/10/2023 09:13 by rivaldo
NAV is now 81.8p compared to the 41.5p share price.

The MMs marked the price down 5% this morning presumably based on the 8% decline in NAV year on year, but I'm happy with the overall performance - much of the NAV loss was on the sale of Exscientia shares against a lower prior year valuation, with the investment portfolio only declining by £0.96m, a pretty decent result in the current climate.

Much of the portfolio is, as stated previously, now coming to fruition. Alusid is planning an IPO next year. A number of companies are generating revenues. Pulsiv could be a gamechanger. Others look highly promising.

FIPP has £4.6m cash and a further £2m of tradeable Exscientia shares. Which renders the qualified audit opinion somewhat odd in respect of both this and the mere 2.6% of NAV re early stage investments which the auditors were unable to conclude on in terms of valuation.

Happy to hold and add further when possible.
Posted at 22/10/2023 19:13 by aqc888
Interesting article, investors have to factor into Frontiers share price however that venture capital success rates are quite low. According to Shikhar Ghosh, a senior lecturer at Harvard Business School, up to 75 percent of venture-backed startups don’t succeed in that they never return cash to their investors. His research also shows that 30 to 40 percent of those 75 percent liquidate assets, with their investors losing all of their money.

Frontier in its backing of exscientia has illustrated it has a proven strong record. Its unique approach to gaining equity stakes at a very early stage ensures they have a broad and cheap entry point to many investments. They can in effect choose which investments to nurture and which to allow to die on the vine. A Darwinist approach other venture companies cannot so much afford to do after paying for equity stakes. Frontiers approach is very time intensive though… however much of this time has already been invested and the current low share price is an abnormally with so many of these investments getting closer to reaching fruition
Posted at 20/9/2023 19:13 by aqc888
Final results due in approximately 5weeks, let’s hope there are some positive surprises as in previous years. Share price rose 29% in the month following last years results.
Posted at 25/7/2023 11:09 by acuere
Sentiment feeling slightly better here. Compared to recently when it was easy to buy at mid price, we now see UT trades at above the offer and 12k sales not crashing the share price
Posted at 20/7/2023 20:00 by acuere
Confirmation today of my previous post

“acuere - 08 Jul 2023 - 22:16:22 - 492 of 502 Frontier IP - FIPP
In last 3 months we have seen Fipps 3 largest holders, Cannacord, Quilter, Octopus, all announce reductions in their holdings. I believe one or more of these are still selling“

Quilter have been selling and are now under 15%. So that’s 547630 shares they’ve dumped in the last 3 months.
The question is are they done now and if not how lowly an share price are they prepared to sell at?
Posted at 03/6/2023 15:24 by aqc888
Share price is dreadful, as are many other AIM companies share prices. So many AIM companies make wild claims which are often unfulfilled. Essentially if we believe in Frontiers portfolio and track record, short term losses are irrelevant despite feeling awfully painful! Frontiers portfolio is not only strong, but positioned in very favourable markets (by luck) created by covid and Russian invasion.
Posted at 23/5/2023 12:47 by acuere
A lot of the AI pharmas jumped sharply yesterday. Exai presenting at SLAS this week and sentences like this from us,
“ We believe that within this decade the design of all new drug candidates will be augmented with AI.” would surely stimulate investors appetite for these stocks. Hopefully Exai can hold these share price gains. Not that it seems to make any difference to Fipp share price Exai are up about 50% this year and yet Fipp over 20% down.

I think we need a juicy Pulsiv announcement or confirmation of Allusid IPO to get things moving in the right direction again.
Posted at 15/3/2023 09:04 by rivaldo
Singer today reiterate their Buy and 125p target price.

The CEO's quote about strong upcoming news flow is particularly good to see.

There are so many exciting developments in the portfolio. Quite apart from the many investees at or beyong inflection points and commercialisation, there are now three graphene tech portfolio companies spun out from Cambridge which could be incredibly exciting.

Pulsiv, Nandi, Alucid, CamGraPhIC, Vaccine Group and Celerum all seem to be making excellent progress.

Singer summarise as follows:

"A maturing portfolio

Frontier IP has reported interim results (H1’23) that reflect a period of strong technical progress but without the large revaluations of previous periods. Net assets per share decreased to 88.2p (FY22: 88.5p) while Net Cash increased to £5.8m providing the Group with a multi-year cash runway. H1’23 saw a number of important commercial and technical developments with FIPP’s management highlighting Pulsiv and Alusid as moving beyond inflection points. A £0.5m pre-tax loss reflects no major net revaluations but Pulsiv and CamGraPhIC raised money in the period and FIPP hosted a well-attended CMD that demonstrated the strength and increasing maturity, of its portfolio. FIPP shares trade at a 22% discount to NAV, we remain at a Buy."

"BUY recommendation

We view FIPP’s NAV as a lagging indicator given multiple milestones are often achieved between mark-to-market valuations. FIPP shares already trade at a 22% discount to NAV before we factor in the potential upside from the Group’s maturing portfolio. We maintain our BUY recommendation and 125p target price."
Posted at 26/1/2023 12:36 by acuere
No Trading Update from Fipp, so in absence of News, share price may well continue to drift until HY results in 6/7 weeks. NAV could be lower as Exai share price on 31st Dec was just $4.99 compared to $10.89 at end June. It has recovered a bit this month to $6.25 and I’m confident when general market sentiment improves it will return to IPO price.

However, like others I believe it is Pulsiv that will be the driving force in the next 12/18m. For this reason I recommend regularly checking their website.
There are 2 new distribution agreements announced in the last week.

These agreements all seem to be putting in place the building blocks for what should be a very profitable company that could attract a generous IPO valuation. The valuation of Fipp 18.3% stake in Pulsiv more than doubled to over £9m last year. It’s easy to see that stake being worth far more than the Groups current £34m market cap when Pulsiv floated off or sold.
Frontier Ip share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |